Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection

Ornella Spagnolello,Claudia Pinacchio,Letizia Santinelli,Paolo Vassalini,Giuseppe Pietro Innocenti,Gabriella De Girolamo,Silvia Fabris,Marta Giovanetti,Silvia Angeletti,Alessandro Russo,Claudio M Mastroianni,Massimo Ciccozzi,Giancarlo Ceccarelli,Gabriella d'Ettorre
DOI: https://doi.org/10.1159/000515344
Chemotherapy
Abstract:Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.
What problem does this paper attempt to address?